Pharmaceuticals News and Research

RSS

Watson Pharmaceuticals acquires Eden Biopharm Group for approximately $15M

Watson Pharmaceuticals, Inc. today announced that it has completed the acquisition of Eden Biopharm Group Limited for approximately $15 million. Eden is a biopharmaceutical development and contract manufacturing company located in Liverpool, UK. As a result of the acquisition of the Arrow Group in December 2009, Watson had previously acquired approximately 36 percent of Eden.

29 Jan 2010

FDA approves LPI's Perindopril Erbumine tablets

Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received final approval from the U.S. Food and Drug Administration (U.S. FDA) for its Perindopril Erbumine tablets, 2mg, 4mg and 8mg. Commercial shipments of the product will commence shortly.

29 Jan 2010

iPierian receives UK patent for induced pluripotent stem cell technology

iPierian, Inc., a biopharmaceutical company focused on changing the paradigm of drug discovery and development through the application of cellular reprogramming, today announced that the Intellectual Property Office in the United Kingdom has issued a Notification of Grant to iPierian for UK patent No. GB2450603, its first patent related to induced pluripotent stem cell (iPSC) technology.

29 Jan 2010

Conatus Pharmaceuticals initiates combination trial of CTS-1027 with pegylated interferon and ribavirin for HCV

Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys®) and ribavirin (Copegus®) in refractory HCV patients. Antiviral activity, safety and tolerability of the triple combination will be assessed after up to 48 weeks of therapy.

28 Jan 2010

ChemoCentryx announces the initiation of Phase I clinical trial of CCX168

ChemoCentryx, Inc., today announced the initiation of a Phase I clinical trial of CCX168, an orally-administered small molecule designed to treat autoimmune diseases.

28 Jan 2010

Ligand Pharmaceuticals acquires Metabasis Therapeutics

Ligand Pharmaceuticals Incorporated announced that it has completed the acquisition of Metabasis Therapeutics, Inc. (NASDAQ:MBRX), following approval of the transaction by Metabasis stockholders yesterday. As a result, Ligand gains a fully funded partnership with Roche, additional pipeline assets and drug discovery technologies and resources. The transaction was first announced on October 27, 2009.

28 Jan 2010

Novella Clinical and OSI Pharmaceuticals expand existing clinical service agreement

Novella Clinical Inc. (formerly PharmaLinkFHI) and OSI Pharmaceuticals, Inc. announced today that the Companies will expand their existing clinical service agreement. Under the terms of the new agreement, effective February 1, 2010, Novella will provide clinical research and related services to OSI for a period of two years as OSI transitions its clinical operations to its new Ardsley, New York campus. Novella will assume use of some of OSI’s facilities in Boulder and employ members of OSI’s Boulder staff.

28 Jan 2010

Merck’s sales representatives ranked second by cardiologists

According to SDI’s recently released 2009 Ranking Tables Study, Merck’s sales representatives were ranked second by cardiologists, a noteworthy increase from sixth place in 2008. Pfizer was ranked first by cardiologists. Schering-Plough, AstraZeneca, and Novartis rounded out the top five, finishing third, fourth, and fifth, respectively.

28 Jan 2010

Life Technologies reports fourth-quarter and fiscal year results ended December 31, 2009

Life Technologies Corporation today announced results for its fourth quarter and full year ending December 31, 2009. Non-GAAP revenue for the fourth quarter was $874 million, resulting in full year non-GAAP revenues of $3.30 billion, an increase of 5 percent over the $3.14 billion reported for 2008, as if Invitrogen and Applied Biosystems had been combined.

From Danaher 28 Jan 2010

Celgene reports total revenue of $758M for fourth-quarter of 2009

Celgene Corporation announced non-GAAP (Generally Accepted Accounting Principles) net income of $290.3 million, or non-GAAP diluted earnings per share of $0.62 for the quarter ended December 31, 2009. Non-GAAP net income for the fourth quarter of 2008 was $200.9 million or non-GAAP diluted earnings per share of $0.43. Based on U.S. GAAP, Celgene reported net income of $254.2 million, or diluted earnings per share of $0.54 for the quarter ended December 31, 2009. GAAP net loss for the fourth quarter of 2008 was $149.3 million, or diluted loss per share of $0.33.

28 Jan 2010

Procter & Gamble reports increased net sales for October - December quarter

The Procter & Gamble Company delivered net sales growth of six percent for the October - December quarter to $21.0 billion. Organic sales grew five percent which was at the top of the Company's guidance range.

28 Jan 2010

Cenduit announces strategic business alliance with invivodata

Cenduit, LLC, and invivodata, inc., today announce a strategic business alliance to further improve clinical trial efficiencies by adding the scientific and operational benefits of invivodata’s electronic Patient Reported Outcomes (ePRO) solutions to the proven efficiencies of Cenduit‘s Interactive Response Technology solution (IRT).

28 Jan 2010

Idera Pharmaceuticals commences IMO-3100 Phase 1 clinical trial for autoimmune diseases

Idera Pharmaceuticals, Inc. today announced initiation of a Phase 1 clinical trial of IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9.

28 Jan 2010

Anacor Pharmaceuticals to present data on its PDE4 inhibitor at the Cytokines and Inflammation Conference

Anacor Pharmaceuticals announced today that it will present a poster and oral presentation on a novel systemic anti-inflammatory candidate, AN6415, at the upcoming 8th Cytokines and Inflammation Conference, taking place January 28-29, 2010 in La Jolla, California.

28 Jan 2010

David Brennan interviewed on AstraZeneca's fourth-quarter and full-year results

Pharmaceutical group AstraZeneca announced it's Q4 and full-year results today with CEO David Brennan saying in a video interview on http://www.cantos.com that cost control and restructuring had helped deliver a revenue line above company expectations.

28 Jan 2010

Men welcome male contraceptive pill currently undergoing trials

Would you trust men to take a 'male pill'? That's the question posed to 380 people in North East England by a team from Teesside University which questioned people about the male contraceptive pill currently undergoing trials.

28 Jan 2010

Repligen announces five-year supply agreement for recombinant Protein A with GE Healthcare Bio-Sciences

Repligen Corporation announced today that it has extended its longstanding relationship with GE Healthcare Bio-Sciences AB by entering into a five-year supply agreement for recombinant Protein A, a consumable used in the manufacture of monoclonal antibodies, a highly successful class of biopharmaceutical. Repligen is the world's leading supplier of recombinant Protein A and has manufactured recombinant Protein A for GE Healthcare for more than 10 years.

28 Jan 2010

MPM Capital leads Alnara Pharmaceuticals' $35M Series B venture capital financing

Alnara Pharmaceuticals, Inc., a pharmaceutical company developing non-systemic, orally-delivered protein therapeutics for the treatment of metabolic diseases, announced today that it has secured $35 million in Series B venture capital financing. The round was led by new investor MPM Capital, joined by current investors Third Rock Ventures, Frazier Healthcare and Bessemer Venture Partners. In conjunction with the MPM investment, managing director Ashley Dombkowski, Ph.D., will join Alnara’s board of directors.

28 Jan 2010

BD announces first-quarter fiscal 2010 results

BD today reported quarterly revenues of $1.917 billion for the first fiscal quarter ended December 31, 2009, representing an increase of 12 percent from the prior-year period, or 9 percent on a foreign currency-neutral basis.

From BD (Becton, Dickinson and Company) 28 Jan 2010

Scientific and regulatory experts to discuss global and domestic public health issues

The United States Pharmacopeial Convention (USP) will convene a meeting of its member organizations on April 21󈞄 in Washington, D.C. Member delegates and experts from around the world will gather to discuss pressing global and domestic public health issues.

28 Jan 2010

Pharmaceuticals News and Research

Watson Pharmaceuticals acquires Eden Biopharm Group for approximately $15M

FDA approves LPI's Perindopril Erbumine tablets

iPierian receives UK patent for induced pluripotent stem cell technology

Conatus Pharmaceuticals initiates combination trial of CTS-1027 with pegylated interferon and ribavirin for HCV

ChemoCentryx announces the initiation of Phase I clinical trial of CCX168

Ligand Pharmaceuticals acquires Metabasis Therapeutics

Novella Clinical and OSI Pharmaceuticals expand existing clinical service agreement

Merck’s sales representatives ranked second by cardiologists

Life Technologies reports fourth-quarter and fiscal year results ended December 31, 2009

Celgene reports total revenue of $758M for fourth-quarter of 2009

Procter & Gamble reports increased net sales for October - December quarter

Cenduit announces strategic business alliance with invivodata

Idera Pharmaceuticals commences IMO-3100 Phase 1 clinical trial for autoimmune diseases

Anacor Pharmaceuticals to present data on its PDE4 inhibitor at the Cytokines and Inflammation Conference

David Brennan interviewed on AstraZeneca's fourth-quarter and full-year results

Men welcome male contraceptive pill currently undergoing trials

Repligen announces five-year supply agreement for recombinant Protein A with GE Healthcare Bio-Sciences

MPM Capital leads Alnara Pharmaceuticals' $35M Series B venture capital financing

BD announces first-quarter fiscal 2010 results

Scientific and regulatory experts to discuss global and domestic public health issues

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence